Abbott announced that the Sekisui CP3000 coagulation system, a fully automated analyzer that tests bleeding and clotting function in blood, is now available in Europe, the Middle East, and Asia Pacific. Abbott is the exclusive global distributor of the CP3000 coagulation system in the U.S.1,2, Europe and other countries that recognize CE Mark and has non-exclusive distribution rights with Sekisui in China, Hong Kong, Japan and Macau.
“The launch of the CP3000 coagulation system is an important milestone in our ongoing efforts to improve care for people around the world. For many of our customers, quickly obtaining reliable test results is critical to their clinical decision making,” said Luis de Luzuriaga, divisional vice president and general manager for Abbott’s hematology business. “Abbott is committed to offering testing solutions, like the CP3000 system, to healthcare providers who provide accurate results and improve the operational performance of their laboratories.”
The CP3000 coagulation system seamlessly integrates with Abbott’s suite of informatics solutions, which help accelerate efficiency in high test volume laboratories where resources may be limited and space and time is at a premium. Capabilities like Abbott’s AlinIQ informatics and service offerings3 streamline operations and provide intelligent laboratory insights through common reporting and dashboard views, make it easy for healthcare providers to read and interpret patient results. The system also connects to the ACCELERATOR a3600 automation track, which provides additional flexibility to meet the needs of the laboratory.
Coagulation tests measure the blood’s ability to clot. Clotting disorders may be a sign of liver disease, thrombophilia (excessive clotting), or hemophilia (inability to clot normally). These tests aid physicians in assessing the patients’ risk of excessive bleeding or clotting and in determining the patient care pathway. Coagulation tests are also performed to monitor patients who are taking medications that can affect clotting.
Delays in coagulation testing are often related to sample errors and manual errors in the testing process. CP3000 coagulation system provides automated, standardized sample management, and can flag unsuitable samples at the start of testing. The system offers an expanded menu of barcoded reagents to reduce data entry errors. With a unique ability to visualize and automate Mixing Studies, the CP3000 coagulation system can help clinicians quickly interpret results.
“The CP3000 coagulation system has been a great addition to our lab. It does not occupy a lot of space, and its automated processes and user-friendly design have reduced the burden on our lab staff and pathologists. We have been pleased with how quickly the system produces accurate results that are used to guide treatment decisions for our patients,” said Dr. Chandra Poonam, Laboratory Director at Gulf Diagnostic Center Hospital in Abu Dhabi, United Arab Emirates.
Alinity HQ Analyzer for Hematology
Abbott also announced that the Alinity hq analyzer for hematology is now CE Marked and available in Europe and other countries that recognize CE Mark. The analyzer is the first in the Alinity hematology series of instruments to be commercially released, and is part of the planned integrated hematology system designed to address the productivity needs of the high-volume laboratory.
Hematology is a medical specialty dedicated to studying the physiology of blood, and the cause, diagnosis, treatment, and prevention of diseases related to blood. In diagnostics testing, hematology tests look at blood composition, which includes the identification and quantification of different types of blood cells. The Alinity hq analyzer automates the performance of these tests and reports on 29 different parameters within a matter of minutes.
